Page last updated: 2024-08-05 11:20:36
pyrazolidines
null
ChEBI ID: 38312
Members (8)
Member | Definition | Role |
---|---|---|
2-Chloro-1-[5-(furan-2-yl)-3-(5-methylfuran-2-yl)-4,5-dihydro-1H-pyrazol-1-yl]ethan-1-one | 2-Chloro-1-[5-(furan-2-yl)-3-(5-methylfuran-2-yl)-4,5-dihydro-1H-pyrazol-1-yl]ethan-1-one | |
3-(2-furanyl)-2-methylsulfonyl-5-thiophen-2-yl-3,4-dihydropyrazole | 3-(2-furanyl)-2-methylsulfonyl-5-thiophen-2-yl-3,4-dihydropyrazole | |
kebuzone | A pyrazolidine that is phenylbutazone in which the two methylene hydrogens at postion 3 on the butyl chain are replaced by an oxo group. | kebuzone |
mofebutazone | A pyrazolidine that is phenylbutazone lacking one of the phenyl substituents. It is used for treatment of joint and muscular pain. | mofebutazone |
oxyphenbutazone | A metabolite of phenylbutazone obtained by hydroxylation at position 4 of one of the phenyl rings. Commonly used (as its hydrate) to treat pain, swelling and stiffness associated with arthritis and gout, it was withdrawn from the market 1984 following association with blood dyscrasis and Stevens-Johnson syndrome. | oxyphenbutazone |
phenylbutazone | A member of the class of pyrazolidines that is 1,2-diphenylpyrazolidine-3,5-dione carrying a butyl group at the 4-position. | phenylbutazone |
sulfinpyrazone | sulfinpyrazone | |
suxibuzone | A pyrazolidine that is phenylbutazone which is substituted by a 3-carboxypropanoylmethyl group at the 4-position. Suxibuzone is a prodrug for phenylbutazone and is commonly used as an anti-inflammatory drug in horses. | suxibuzone |
Research
Studies (7,445)
Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
---|---|---|
pre-1990 | 6,727 (90.36) | 18.7374 |
1990's | 328 (4.41) | 18.2507 |
2000's | 217 (2.91) | 29.6817 |
2010's | 135 (1.81) | 24.3611 |
2020's | 38 (0.51) | 2.80 |
Study Types
Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
---|---|---|
Trials | 645 (7.37%) | 5.53% |
Reviews | 452 (5.16%) | 6.00% |
Case Studies | 368 (4.20%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7,290 (83.27%) | 84.16% |